ClinicalTrials.gg
Not yet recruitingNCT06666010PATSUDUpdated Oct 30, 2024

PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study

A Phase 2 interventional study of PEX010-Assisted Therapy and PEX010(01) in Stimulant Use Disorder, sponsored by Filament Health Corp.. Not yet recruiting. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Filament Health Corp. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if PEX010 is effective for the treatment of Stimulant Use Disorder in adults. The study will also assess the safety and feasibility of administering PEX010 to this population. The main questions it aims to answer are:

Does PEX010 reduce stimulant use?

What medical problems do participants experience when taking PEX010?

Researchers will compare an active PEX010 dose containing 25 mg psilocybin to an active placebo arm, to see if PEX010 works to reduce stimulant use.

Participants will:

Take PEX010 or the active placebo once during the study, engage in cognitive behavioural therapy, and visit the clinic twice weekly for study intervention and follow-up assessments.

Read the detailed description

In this randomized, controlled trial study participants will receive one capsule of PEX010 containing 25 mg or 1 mg of psilocybin, in conjunction with therapy.

Following screening and baseline visits, participants will receive 2 preparation sessions, 1 PEX010 dosing session, 1 integration session, and 7 follow-up visits.

02

Conditions studied

  • Stimulant Use Disorder
03

In context

Lead sponsor

Filament Health Corp. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are between 19 and 65 years old.
  • Have signed the form for the study
  • Have moderate to severe amphetamine stimulant use disorder (ASUD) as determined by the Mini-International Neuropsychiatric Interview (MINI 7.0.1), and clinical review by the study physician. The focus will be on illicit methamphetamine use.
  • Are treatment-seeking but not currently receiving other treatments for SUD.
  • Have stable housing.
  • Have a local support person (close friend or family member) that is available to accompany them home from the study drug session.
  • Are of non- and/or using adequate methods as defined by Health Canada.
  • Non-childbearing potential is defined as (i) self-reported status (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgical sterilization
  • Have a negative pregnancy test at screening and prior to the study drug session. Must agree to use adequate contraception through 10 days after the study drug session. Adequate contraception methods include intrauterine devices, oral hormones plus barrier contraception, abstinence, injectable or implanted hormonal methods, or vasectomized/non-sperm carrying sole partner. Barrier methods alone are not considered effective methods of contraception.
  • Be willing to refrain from caffeine for ≥12 hours, cannabis and stimulants for ≥24 hours, and all other drugs for ≥5 days prior to PEX010 administration such that there are no clinical signs of intoxication or withdrawal.
  • Able and willing to follow study procedure.
  • Able to understand and communicate in English.
  • Complete the Columbia Suicide Severity Rating Scale (CSSRS)
  • Results from safety laboratory tests (CBC, and ALT, TSH, ) are within normal limits.

Exclusion criteria

Exclusion Criteria:

  • Are experiencing or at risk for significant withdrawal.
  • Have any medical condition that would be , including previously diagnosed conditions:
  • seizure disorder or history of seizures;
  • a history of significantly impaired hepatic function;
  • a history of unstable or uncontrolled cardiovascular disease (coronary artery disease, heart failure, abnormality);
  • uncontrolled hypertension, resting blood pressure > 140/90 mmHg; baseline prolongation of : >450 ms in both males and females;
  • a history of major central nervous system disease (history of cerebrovascular accident, masses, aneurysm);
  • a history of uncontrolled obstructive airway disease or significant respiratory compromise;
  • a history of uncontrolled thyroid disease;
  • a history of uncontrolled insulin dependent diabetes that may preclude safe participation in the study;
  • a history of narrow-angle glaucoma;
  • gastrointestinal conditions which may affect psilocybin absorption (i.e. stenosing peptic ulcer, pyloroduodenal obstruction);
  • a history of active obstructive urological conditions (i.e. symptomatic prostatic hypertrophy, bladder-neck obstruction) that may preclude safe participation in the study.
  • Have a personality disorder deemed to be high risk (antisocial, borderline, narcissistic) assessed via the SCID-5-PD.
  • Have a personal history or family history of either mania/hypomania or psychosis, including substance-induced psychosis.
  • Have any history of Hallucinogen Perception Disorder
  • Have a history of suicide attempt within the last 6 years or a suicidal ideation in the last year.
  • Are currently taking medications with known interactions with psilocybin (e.g., antidepressants, antipsychotics)
  • Are pregnant, breastfeeding, or not using adequate if of .
  • Any other finding(s) based on the screening process that the investigator determines makes the candidate unsuitable for the study
  • Results from safety laboratory tests (CBC, and ALT, TSH, ) are not within normal limits
  • Have baseline heart rate outside of normal limits (e.g., >100 beats per minute).
  • Subjects currently on medications with serotonergic activity, or taking inhibitors of UGT1A9, UGT1A10, MAO and aldehyde or alcohol dehydrogenase.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Adult participants with confirmed StUD - Active

    PEX010 containing 25 mg psilocybin

    Drug: PEX010-Assisted Therapy

  • Placebo comparator
    Adult participants with confirmed StUD - Placebo

    PEX010 containing 1 mg psilocybin

    Drug: PEX010(01)

Interventions

  • DrugPEX010-Assisted Therapy

    The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.

  • DrugPEX010(01)

    The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.

06

What researchers measure

Primary outcomes

  1. Changes in Amphetamine-type Stimulant Use

    The difference between treatment and active placebo groups in the proportion of subjects abstinent from illicit methamphetamine use over the course of the 3-month assessment period assessed by Timeline Followback (TLFB) and urine drug tests (UDT).

    Time frame: 3 Months

Secondary outcomes

  1. Number of AEs and SAEs

    Total number of adverse events (AEs) and serious adverse events (SAEs) reported during the 3-month assessment period.

    Time frame: 3 Months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Jan 2028, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Oct 30, 2024
StartEst.
Jan 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2028
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06666010
Lead sponsor
Filament Health Corp.
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Jan 2025 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 30, 2024

Study contacts

Lisa Ranken
Contact
lisa@filament.health
250-212-1169

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion